Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

995 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Introduction of continuous glucose monitoring (CGM) is a key factor in decreasing HbA1c in war refugee children with type 1 diabetes.
Neuman V, Vavra D, Drnkova L, Pruhova S, Plachy L, Kolouskova S, Obermannova B, Amaratunga SA, Konecna P, Vyzralkova J, Venhacova P, Pomahacova R, Paterova P, Stichova L, Skvor J, Kocourkova K, Romanova M, Vosahlo J, Strnadel J, Polockova K, Neumann D, Slavenko M, Sumnik Z. Neuman V, et al. Among authors: neumann d. Diabetes Res Clin Pract. 2024 Feb;208:111118. doi: 10.1016/j.diabres.2024.111118. Epub 2024 Feb 1. Diabetes Res Clin Pract. 2024. PMID: 38309536
Glycemic Control by Treatment Modalities: National Registry-Based Population Data in Children and Adolescents with Type 1 Diabetes.
Šumnik Z, Pavlíková M, Neuman V, Petruželková L, Konečná P, Venháčová P, Škvor J, Pomahačová R, Neumann D, Vosáhlo J, Strnadel J, Kocourková K, Obermannová B, Šantová A, Plachý L, Průhová S, Cinek O; ČENDA Project Group. Šumnik Z, et al. Among authors: neumann d. Horm Res Paediatr. 2024;97(1):70-79. doi: 10.1159/000530833. Epub 2023 Apr 26. Horm Res Paediatr. 2024. PMID: 37100041 Free article.
Are all HCL systems the same? long term outcomes of three HCL systems in children with type 1 diabetes: real-life registry-based study.
Santova A, Plachy L, Neuman V, Pavlikova M, Petruzelkova L, Konecna P, Venhacova P, Skvor J, Pomahacova R, Neumann D, Vosahlo J, Strnadel J, Kocourkova K, Obermannova B, Pruhova S, Cinek O, Sumnik Z. Santova A, et al. Among authors: neumann d. Front Endocrinol (Lausanne). 2023 Oct 16;14:1283181. doi: 10.3389/fendo.2023.1283181. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37908748 Free PMC article.
Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr, Bode B, Aronoff S, Holland C, Carlin D, King KL, Wilder RL, Pillemer S, Bonvini E, Johnson S, Stein KE, Koenig S, Herold KC, Daifotis AG; Protégé Trial Investigators. Sherry N, et al. Lancet. 2011 Aug 6;378(9790):487-97. doi: 10.1016/S0140-6736(11)60931-8. Epub 2011 Jun 28. Lancet. 2011. PMID: 21719095 Free PMC article. Clinical Trial.
The Longer, the Better: Continuous Glucose Monitoring Use for ≥90% Is Superior to 70%-89% in Achieving Tighter Glycemic Outcomes in Children with Type 1 Diabetes.
Santova A, Neuman V, Plachy L, Amaratunga SA, Pavlikova M, Romanova M, Konecna P, Neumann D, Kocourkova K, Strnadel J, Pomahacova R, Venhacova P, Skvor J, Obermannova B, Pruhova S, Cinek O, Sumnik Z; ČENDA Project Group. Santova A, et al. Among authors: neumann d. Diabetes Technol Ther. 2025 Jan 6. doi: 10.1089/dia.2024.0472. Online ahead of print. Diabetes Technol Ther. 2025. PMID: 39761072
CRISPR-Cas9-mediated genome editing delivered by a single AAV9 vector inhibits HSV-1 reactivation in a latent rabbit keratitis model.
Amrani N, Luk K, Singh P, Shipley M, Isik M, Donadoni M, Bellizzi A, Khalili K, Sariyer IK, Neumann D, Gordon J, Ruan GX. Amrani N, et al. Among authors: neumann d. Mol Ther Methods Clin Dev. 2024 Aug 14;32(3):101303. doi: 10.1016/j.omtm.2024.101303. eCollection 2024 Sep 12. Mol Ther Methods Clin Dev. 2024. PMID: 39610766 Free PMC article.
An allosteric inhibitor of RhoGAP class-IX myosins suppresses the metastatic features of cancer cells.
Kyriazi D, Voth L, Bader A, Ewert W, Gerlach J, Elfrink K, Franz P, Tsap MI, Schirmer B, Damiano-Guercio J, Hartmann FK, Plenge M, Salari A, Schöttelndreier D, Strienke K, Bresch N, Salinas C, Gutzeit HO, Schaumann N, Hussein K, Bähre H, Brüsch I, Claus P, Neumann D, Taft MH, Shcherbata HR, Ngezahayo A, Bähler M, Amiri M, Knölker HJ, Preller M, Tsiavaliaris G. Kyriazi D, et al. Among authors: neumann d. Nat Commun. 2024 Nov 16;15(1):9947. doi: 10.1038/s41467-024-54181-6. Nat Commun. 2024. PMID: 39550360 Free PMC article.
995 results